Pavitra Ramachandran
Head of Ocular In Vivo Translational Sciences Sanofi
Pavitra is Distinguished Scientist and Head of Ocular In Vivo Translational Sciences at Sanofi, where she leads preclinical and translational strategies supporting the development of innovative therapies for ocular diseases. With more than a decade of experience across gene, RNA-based, and genomic medicines, she has successfully advanced programs from discovery through IND-enabling studies. Before joining Sanofi, Pavitra scientific leadership roles at Stoke Therapeutics, Gemini Therapeutics, Vertex Pharmaceuticals, and the University of Pennsylvania. Her expertise spans translational pharmacology, biomarker development, ophthalmic drug development, and cross-functional program leadership, driving the translation of cutting-edge science into clinical impact.
Seminars
- Discuss common causes of translational disconnect in efficacy, durability, safety, and immunogenicity from preclnical studies to humans
- Compare the strengths and limitations of rodent, rabbit, minipig, and nonhuman primate models for disease modeling, PK/PD characterization, biodistribution, and safety assessment.
- Discuss the potential of organoids, microphysiological systems, ex vivo human ocular tissues, and computational modeling to complement or replace traditional animal studies.
- Discuss common deficiencies, evidence gaps, or study design limitations that lead to regulatory questions, delays, or clinical holds for preclinical IND packages
- Discuss how to select the most predictive animal models for your delivery route, formulation, and indication by understanding the strengths and limitations of rabbit, non-human primate, and minipig studies
- Determine when disease models provide meaningful pharmacodynamic insights
- Reduce development timelines, costs, and regulatory risk through strategic non-GLP and GLP study planning that supports stronger IND submissions
